{"_self":{"principle":"Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.","widget":"article_bundle","feature":"bundle","name":"LLM article bundle","what":"Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution.","contains":"body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest","slug":"tesamorelin-muscle-loss","urls":{"read":"https://miscsubjects.com/api/articles/tesamorelin-muscle-loss/bundle?format=markdown"},"how_to_use":"Reference bundle for an LLM or reader. §SELF explains the surface; ingest and claim endpoints in llm_manifest are the write-back routes.","write":null,"imessage":null,"router_tag":null,"proof_chain":[{"step":1,"claim":"Articles are voxel graphs of tiered claims, not prose blobs.","verify":"https://miscsubjects.com/api/articles/constitution"},{"step":2,"claim":"Claims link to hash-chained sources via source_ids.","verify":"https://miscsubjects.com/api/articles/tesamorelin-muscle-loss/sources"},{"step":3,"claim":"Ask reads topology; ingest/claim append to ledger.","verify":"https://miscsubjects.com/api/protocol"},{"step":4,"claim":"Models queue growth: populate → collaborate → repair → reflex.","verify":"https://miscsubjects.com/api/protocol/grow"},{"step":5,"claim":"Graph proves its own shape (reflex) and $/claim (yield).","verify":"https://miscsubjects.com/graph.html?layer=reflex"},{"step":6,"claim":"Full feature index + _explain on every API response.","verify":"https://miscsubjects.com/api/articles/system-map"}],"related_features":[{"id":"topology","name":"Article topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","urls":{"read":"https://miscsubjects.com/api/articles/tesamorelin-muscle-loss/topology"}},{"id":"voxels","name":"Voxel graph","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance.","urls":{"read":"https://miscsubjects.com/api/articles/tesamorelin-muscle-loss/voxels","write":"https://miscsubjects.com/api/protocol/claim"}},{"id":"ask","name":"Ask protocol","what":"Answer only from topology; creates question_node with gaps and ingest_hint.","urls":{"read":"https://miscsubjects.com/api/articles/tesamorelin-muscle-loss/prompts","write":"https://miscsubjects.com/api/protocol/ask"}},{"id":"ingest","name":"Ingest protocol","what":"Parse pasted evidence → source ledger + claims + evidence_ingest node.","urls":{"write":"https://miscsubjects.com/api/protocol/ingest"}},{"id":"claim_post","name":"Claim post protocol","what":"Prompt-injection style POST — one claim voxel with who_claims + posted_by.","urls":{"read":"https://miscsubjects.com/api/articles/tesamorelin-muscle-loss/voxels","write":"https://miscsubjects.com/api/protocol/claim"}},{"id":"llm_manifest","name":"LLM manifest","what":"Machine-readable read/write contract for external LLMs.","urls":{"read":"https://miscsubjects.com/api/articles/llm-manifest"}}],"system_map":"https://miscsubjects.com/api/articles/system-map","system_map_markdown":"https://miscsubjects.com/api/articles/system-map?format=markdown","not_medical_advice":true},"_explain":{"feature":"bundle","name":"LLM article bundle","what":"Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution.","why":"Every feature is auditable collective intelligence","how":"Reference bundle for an LLM or reader. §SELF explains the surface; ingest and claim endpoints in llm_manifest are the write-back routes.","model":null,"verifies":null,"urls":{"read":"https://miscsubjects.com/api/articles/tesamorelin-muscle-loss/bundle?format=markdown"},"imessage":null,"router":null,"related":[{"id":"topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER."},{"id":"voxels","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance."},{"id":"ask","what":"Answer only from topology; creates question_node with gaps and ingest_hint."},{"id":"ingest","what":"Parse pasted evidence → source ledger + claims + evidence_ingest node."},{"id":"claim_post","what":"Prompt-injection style POST — one claim voxel with who_claims + posted_by."},{"id":"llm_manifest","what":"Machine-readable read/write contract for external LLMs."}],"not_medical_advice":true},"MASTHEAD":{"sorry_status":"planes not merged yet — sorry-status activates after voxel-merge-planes","identity":{"slug":"tesamorelin-muscle-loss","version":2,"content_hash":"1fc7c99e0fb6ccfb9e96473b3ca8696008fab4fc7b0ebc642ebeaa71097037f0","thread_head":"genesis","divs":19},"thesis":{"root_claim":"c1","text":"In a secondary analysis of randomized trials, tesamorelin responders (visceral fat loss ≥8%) showed greater increases in trunk muscle density (1.56–4.86 HU) and lean muscle area (0.64–1.08 cm²) vs placebo after 26 weeks.","tier":"human"},"load_bearing":[{"id":"c2","tier":"human","status":"active","text":"Meta-analysis of tesamorelin trials reported a mean lean body mass increase of 1.42 kg alongside visceral fat reduction."},{"id":"c3","tier":"human","status":"active","text":"An ongoing clinical trial (NCT06554717) is evaluating tesamorelin plus exercise for physical function and muscle health in adults with HIV."},{"id":"c4","tier":"anecdotal","status":"active","text":"Reddit users report lean mass preservation or modest gains alongside visceral fat loss when using tesamorelin in calorie deficits, often with improved recovery."}],"standing_objections":{"open":0,"strongest_open":null,"link":"https://miscsubjects.com/api/articles/tesamorelin-muscle-loss/discourse"},"verbs":{"read":"GET https://miscsubjects.com/api/articles/tesamorelin-muscle-loss/voxels — DIVs + hashes + chains (free)","read_claims":"GET https://miscsubjects.com/api/articles/tesamorelin-muscle-loss/claims — every formal claim as claim:<id> with current hash, thread, stable link, and exact contribution/edit bodies","challenge":"POST https://miscsubjects.com/api/protocol/voxel-challenge {slug, expected_thread_head, target_div?, expected_hash?, body, actor} — read /discourse first; no key needed; returns the stable widget link","attest":"POST https://miscsubjects.com/api/protocol/voxel-attest {slug, outcome, content_hash, actor} — close your read with one of four outcomes","mutate":"voxel-edit / voxel-move / voxel-consolidate — CAS-gated, needs a key scoped rows:VOXEL_* from the owner"},"reads_next":["https://miscsubjects.com/a/philosophy","https://miscsubjects.com/api/articles/tesamorelin-muscle-loss/discourse","https://miscsubjects.com/api/protocol"]},"bundle_version":1,"generated_at":"2026-07-30T03:51:30.893Z","slug":"tesamorelin-muscle-loss","title":"Tesamorelin for Muscle Loss: Human Evidence on Lean Mass, Muscle Density, and the GH Axis","url":"https://miscsubjects.com/a/tesamorelin-muscle-loss","register":"source_ledger","tags":["peptide","matrix"],"posted_at":"2026-06-29T21:33:33.546Z","updated_at":"2026-07-17T02:42:24.087Z","body":"## What's breaking down\nMuscle loss, or sarcopenia-like decline, often stems from reduced growth hormone (GH) signaling with age or illness. This lowers IGF-1, slowing protein synthesis while catabolic processes continue. Visceral fat accumulation adds mechanical and inflammatory stress that can further impair muscle quality. In HIV-related lipodystrophy, excess abdominal fat pairs with muscle fat infiltration and reduced lean area. Repair pathways lag behind breakdown when GH pulses weaken. Tesamorelin is discussed here because studies examine its effect on the GH axis and downstream tissue changes rather than symptom masking.\n\n## Why Tesamorelin might help you\nIf your muscle loss involves low GH/IGF-1 activity or excess visceral fat, the logic chain runs like this. Tesamorelin stimulates the pituitary to release endogenous GH in a more physiologic pattern. That raises circulating IGF-1. Higher IGF-1 supports protein synthesis in muscle tissue. In people who respond with visceral fat reduction, CT scans showed measurable gains in trunk muscle density and lean muscle area over 26 weeks. Therefore, if visceral fat or poor muscle quality is part of your profile, the compound is studied for its potential to shift the balance toward tissue-level repair signals instead of only lowering fat mass.\n\nStep 1: GH release increases. Step 2: IGF-1 rises in a pulsatile way. Step 3: Muscle protein turnover favors synthesis. Step 4: In responders, muscle fat decreases and lean area increases on imaging. This targets the regenerative side of the equation for the layers listed above.\n\n## How these fit together\nSingle-compound focus. Tesamorelin maps directly to the GH axis and visceral fat layer. If your situation includes multiple degeneration layers, this agent addresses the endocrine and body-composition component. Other approaches would need separate evaluation for neural, sleep, or direct anabolic layers.\n\n## What the evidence actually shows\nHuman data come from secondary analyses of randomized trials in adults with HIV and abdominal obesity. One key study (Adrian et al.) restricted analysis to tesamorelin responders who lost at least 8% visceral adipose tissue. Compared with placebo, these participants showed statistically significant increases in muscle density (1.56–4.86 Hounsfield units across trunk muscle groups) and lean muscle area (0.64–1.08 cm²). A later meta-analysis reported a mean lean body mass increase of 1.42 kg. An ongoing trial (NCT06554717) is testing tesamorelin plus exercise for physical function in HIV. No large human trials exist for primary sarcopenia in non-HIV populations. Animal data on muscle-specific outcomes with tesamorelin are not prominent in the reviewed sources. Reddit and X reports remain anecdotal.\n\n## What scientists say\nThe authors of the 2019 Journal of Frailty & Aging paper conclude that among responders, tesamorelin increased skeletal muscle area and density. They note the changes occurred alongside visceral fat reduction and call for longer-term studies on functional impact outside HIV. Reviews emphasize that lean mass gains occur without proportional subcutaneous fat loss or major glycemic disruption in the studied cohorts. Researchers highlight that benefits appear tied to visceral fat responders rather than universal.\n\n## What people say on Reddit\nUsers in peptide communities describe tesamorelin as helping preserve lean mass during calorie deficits. One post states: “Tesa is a tool that raises IGF-1 levels which can in turn preserves muscle mass in a calories deficit and potentially build lean muscle.” Another reports: “Even with zero exercise my lean muscle mass increased by about 15%, visceral fat reduction by 80%.” Several mention better recovery and visible muscle definition when combined with training, though scale weight often stays stable because fat loss offsets any lean gain. Experiences vary; some note waist reduction without overall weight change.\n\n## What people say on X\nPublic posts on X referencing tesamorelin and muscle are sparse in current searches. Most discussion echoes the clinical focus on visceral fat reduction and secondary lean mass observations from the HIV trials. Anecdotal functional claims appear less frequently than on Reddit.\n\n## What we do not know\nHuman evidence is concentrated in HIV populations with abdominal obesity. Direct trials in age-related sarcopenia or non-HIV muscle loss are absent. Long-term (>26 weeks) effects on muscle strength, physical performance, or fracture risk remain unmeasured in published data. Whether gains persist after stopping treatment is unknown. Interactions with resistance training protocols or other body-composition interventions need further controlled study. Effects on muscle in women or diverse ethnic groups are underrepresented.\n\n## Safety and limits\nReported adverse events in trials include injection-site reactions, arthralgia, myalgia, and paresthesia. No major glucose dysregulation appeared in the meta-analysis. Human data are limited to specific responder subgroups and short-to-medium durations. Individual responses differ, and imaging changes do not automatically equal improved daily function. All observations come from controlled settings; real-world variability is higher.","claims":[{"id":"c1","text":"In a secondary analysis of randomized trials, tesamorelin responders (visceral fat loss ≥8%) showed greater increases in trunk muscle density (1.56–4.86 HU) and lean muscle area (0.64–1.08 cm²) vs placebo after 26 weeks.","tier":"human","weight":0.8,"effective_weight":0.8,"slot":null,"source_ids":["s1"],"who_claims":"grok/grok-4.3","status":"active"},{"id":"c2","text":"Meta-analysis of tesamorelin trials reported a mean lean body mass increase of 1.42 kg alongside visceral fat reduction.","tier":"human","weight":0.8,"effective_weight":0.22,"slot":null,"quote_gated":true,"source_ids":["s2"],"who_claims":"grok/grok-4.3","status":"active"},{"id":"c3","text":"An ongoing clinical trial (NCT06554717) is evaluating tesamorelin plus exercise for physical function and muscle health in adults with HIV.","tier":"human","weight":0.8,"effective_weight":0.22,"slot":null,"quote_gated":true,"source_ids":["s3"],"who_claims":"grok/grok-4.3","status":"active"},{"id":"c4","text":"Reddit users report lean mass preservation or modest gains alongside visceral fat loss when using tesamorelin in calorie deficits, often with improved recovery.","tier":"anecdotal","weight":0.3,"effective_weight":0.22,"slot":null,"quote_gated":true,"source_ids":["s4","s5"],"who_claims":"grok/grok-4.3","status":"active"}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/31237318/","title":"The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV","summary":"Secondary analysis of two RCTs; CT-based muscle metrics in responders.","quote":"tesamorelin was effective in increasing skeletal muscle area and density","quote_status":"verified","link_status":"ok","claim_ids":["c1"],"hash":"b0762e1a20bcb7ca"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41545261/","title":"A meta-analysis of randomized controlled trials","summary":"Pooled body composition outcomes from tesamorelin trials in HIV lipodystrophy.","quote":"A significant increase in lean body mass was observed (MD=1.42 kg, 95% CI [1.13, 1.71]; P < 0.001)","quote_status":"unverified","link_status":"ok","claim_ids":["c2"],"hash":"96428706c2883c39"},{"id":"s3","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT06554717","title":"Tesamorelin as an Adjunct to Exercise for Improving Physical Function and Muscle Health in Adults With HIV","summary":"Active trial combining tesamorelin with exercise.","quote":"learn whether the medication tesamorelin will improve physical function and muscle health","quote_status":"unverified","link_status":"ok","claim_ids":["c3"],"hash":"3efea45c7c0c600b"},{"id":"s4","type":"reddit","url":"https://www.reddit.com/r/USPeptides/comments/1p3bh79/tesamorelin_belly_fat_reduction_growth_hormone/","title":"Tesamorelin Belly Fat Reduction","summary":"User discussion on muscle preservation.","quote":"Tesa is a tool that raises IGF-1 levels which can in turn preserves muscle mass in a calories deficit","quote_status":"unverified","link_status":"ok","claim_ids":["c4"],"hash":"29bc4fe1e1f6416b"},{"id":"s5","type":"reddit","url":"https://www.reddit.com/r/Biohackers/comments/1qlnwf7/starting_tesamorelin_next_week_advice_needed/","title":"Starting Tesamorelin","summary":"Self-reported body composition changes.","quote":"Even with zero exercise my lean muscle mass increased by about 15%","quote_status":"unverified","link_status":"ok","claim_ids":["c4"],"hash":"500a99f3722c7580"}],"voxels":{"slug":"tesamorelin-muscle-loss","counts":{"divs":19,"voxels":4,"sources":5,"edges":9},"note":"slim bundle — full voxels at /api/articles/tesamorelin-muscle-loss/voxels"},"constitution":{"url":"https://miscsubjects.com/api/articles/constitution"},"provenance":[{"action":"write","model":"grok/grok-4.3","ts":"2026-06-29T23:19:00.263Z","hash":"b893f8d91bcfbfd4","tokens_in":28916,"tokens_out":3094},{"action":"voxel_divide","model":"owner","ts":"2026-07-17T02:42:24.087Z","hash":"19fbfa92b36bdaf0","tokens_in":0,"tokens_out":0}],"contributions":[{"id":"k1","ts":"2026-06-29T23:19:00.263Z","model":"grok/grok-4.3","role":"writer","action":"redraft","rationale":"","hash":"d531986ced9cab26dc5f9ff393cb4ce2acdedea1998974b4ef45145e7f6e6c8f"}],"topology":null,"slim":true,"ledger_totals":{"claims":4,"sources":5,"exported_claims":4,"exported_sources":5},"question_graph":{"slug":"tesamorelin-muscle-loss","questions":[],"evidence":[],"edges":[],"counts":{"questions":0,"evidence":0,"edges":0}},"verification":{"provenance":{"valid":true,"entries":2,"head":"19fbfa92b36bdaf0eb9f55164dc454f801ea701aad9e0d7c424975e61ff55919"},"sources":{"valid":true,"entries":5,"head":"500a99f3722c7580a8a5679617ef7f79b2f3e68ec2b52837a913d9e8591d5e60"}},"counts":{"claims":4,"sources":5,"provenance":2,"contributions":1,"questions":0,"evidence_ingests":0,"voxel_edges":9},"transport":"Open every URL in this bundle with your browser or web / URL-fetch tool. Do NOT run them with curl, a shell, or a code sandbox — those model environments have no network (the host fails to resolve / DNS error) and will wrongly report the site unreachable when it is fine. Opening the link IS the call.","llm_manifest":{"version":"1","site":"https://miscsubjects.com","purpose":"Peptide evidence articles with hash-chained source ledgers, tiered claims, and a question graph. LLMs should READ bundles/URLs and WRITE back via ingest — never invent doses.","read":{"human_page":"https://miscsubjects.com/a/tesamorelin-muscle-loss","bundle_json":"https://miscsubjects.com/api/articles/tesamorelin-muscle-loss/bundle","bundle_markdown":"https://miscsubjects.com/api/articles/tesamorelin-muscle-loss/bundle?format=markdown","topology":"https://miscsubjects.com/api/articles/tesamorelin-muscle-loss/topology","question_graph":"https://miscsubjects.com/api/articles/tesamorelin-muscle-loss/question-graph","sources":"https://miscsubjects.com/api/articles/tesamorelin-muscle-loss/sources","provenance":"https://miscsubjects.com/api/articles/tesamorelin-muscle-loss/provenance","contributions":"https://miscsubjects.com/api/articles/tesamorelin-muscle-loss/contributions","graph_topology":"https://miscsubjects.com/api/articles/tesamorelin-muscle-loss/graph-topology?question={question}","voxels":"https://miscsubjects.com/api/articles/tesamorelin-muscle-loss/voxels","constitution":"https://miscsubjects.com/api/articles/constitution","ontology":"https://miscsubjects.com/api/articles/ontology","system_map":"https://miscsubjects.com/api/articles/system-map","system_map_markdown":"https://miscsubjects.com/api/articles/system-map?format=markdown","health":"https://miscsubjects.com/api/articles/tesamorelin-muscle-loss/health","repair":"POST https://miscsubjects.com/api/protocol/repair","list_articles":"https://miscsubjects.com/api/articles","graph_canvas":"https://miscsubjects.com/graph.html?slugs=tesamorelin-muscle-loss","graph_yield":"https://miscsubjects.com/api/graph?slugs=tesamorelin-muscle-loss&layer=yield","obsidian_vault":"https://miscsubjects.com/api/articles/obsidian-vault?slugs=tesamorelin-muscle-loss","graph_query":"https://miscsubjects.com/api/v1/query?from=tesamorelin-muscle-loss&kind=claim&where=tier=human"},"ask":{"description":"Answer only from topology; creates a question_node with gaps.","api":"POST https://miscsubjects.com/api/protocol/ask","body":{"slug":"{slug}","question":"string"},"imessage":"tesamorelin-muscle-loss|your question","router_tag":"[ARTICLE_ASK]tesamorelin-muscle-loss|question[/ARTICLE_ASK]","auth":"x-terminal-key header for API; iMessage/WhatsApp via miscsubjects build"},"ingest":{"description":"Parse pasted evidence → source ledger + claims + evidence_ingest node.","api":"POST https://miscsubjects.com/api/protocol/ingest","body":{"slug":"{slug}","evidence":"paste text","question_node_id":"optional qn_..."},"imessage":"ingest tesamorelin-muscle-loss|q:{node_id}|paste evidence","router_tag":"[ARTICLE_INGEST]tesamorelin-muscle-loss|evidence[/ARTICLE_INGEST]","tiers":["human","preclinical","anecdotal","mechanistic","speculative"]},"claim":{"description":"Prompt-injection style POST — one claim voxel with who_claims + posted_by provenance.","api":"POST https://miscsubjects.com/api/protocol/claim","body":{"slug":"{slug}","text":"one assertion","tier":"human|preclinical|anecdotal|mechanistic|speculative","who_claims":"study author, platform, or model id","source_ids":"optional [s1]"},"imessage":"claim tesamorelin-muscle-loss|tier|assertion — who claims it?","router_tag":"[ARTICLE_CLAIM]tesamorelin-muscle-loss|tier|assertion[/ARTICLE_CLAIM]","slots":["what_it_is","who_claims_what","what_is_known","what_is_unknown","mechanism","limitations","disclaimer"]},"tiers":{"human":0.8,"preclinical":0.5,"anecdotal":0.3,"mechanistic":0.3,"speculative":0.1},"invariants":["Self-explaining — every API JSON has _self; every paste widget has §SELF; root index at /api/articles/system-map","Append-only — revisions preserved at ?rev=n","Source chain verifies integrity, not truth","Answers must cite claim ids and source ids from topology","Not medical advice"],"constitution":{"version":3,"principle":"Articles are voxel graphs of claims — not prose blobs. Every assertion is a claim atom with tier, weight, source_ids, and posted_by provenance.","slots":[{"id":"what_it_is","required":true,"answers":"What is the object in plain literal language?"},{"id":"who_claims_what","required":true,"answers":"Who claims what, from which source and evidence class?"},{"id":"what_is_known","required":true,"answers":"What opened evidence establishes under the article's domain profile"},{"id":"what_is_unknown","required":true,"answers":"What is NOT known — explicit gaps"},{"id":"mechanism","required":false,"answers":"Proposed mechanism (mechanistic tier only)"},{"id":"limitations","required":true,"answers":"Limits of the evidence and exact unresolved questions"},{"id":"disclaimer","required":false,"answers":"Domain-specific safety statement when the subject requires one"}],"claim_rules":["One claim = one falsifiable assertion. No compound claims.","Every claim must declare tier: human|preclinical|anecdotal|mechanistic|speculative|system.","system tier = architecture/design axioms (not biological mechanism). Use for protocol self-definition.","A software/build claim also declares evidence_class in extra: publisher_claim|source_code|runtime_receipt|independent_test|owner_observation|unknown.","Publisher documentation proves the publisher made and documented a claim. It is not independent runtime proof.","Source code proves an implementation exists. A successful receipt proves one invocation. Neither proves general reliability or field superiority.","Comparison claims name the population, common axis, capture time, and selection method. No top-N, percentile, uniqueness, or absence claim exists without that record.","Sourced claims must cite source_ids from the hash-chained ledger.","Unsourced claims must set source_status: unsourced and why_material.","posted_by is mandatory on every new claim (model id, human, or channel).","No medical advice, no doses, no 'you should take'.","Bad information is retracted (status:retracted), never deleted — retraction event stays on ledger.","Adversary challenges link via challenges[] / challenged_by[] — target may be downweighted.","Leaked secrets are scrubbed to [REDACTED:secret-leak] with scrub_events tombstone — honest audit trail."],"source_rules":["Every source is a voxel edge: type, url, exact quote, summary, found_by, accessed_at.","Sources hash-chain — prev/hash on append.","Anecdotal sources must name platform (reddit|x|youtube|imessage|user_entry).","Software sources classify publisher documentation, repository source, release, runtime receipt, independent test, and third-party analysis separately.","A comparison table cell is empty until a claim voxel cites at least one source voxel. Model prose alone is not evidence."],"writing_rules":["Literal nouns and verbs. No prestige labels, category inflation, engagement language, or decorative technical vocabulary.","Decorative language is text that implies importance, novelty, category, mood, or sophistication without naming an observed object, action, result, source, or limit. Delete it.","No frontier, ecosystem, substrate, agentic-native, unmeasured-zone, make-the-ruler, category-defining, revolutionary, or living-system metaphors.","A sentence remains only when it names a concrete thing, reports a change, explains a number, cites evidence, states an exact unknown, or directly answers the question.","Technical nouns are allowed only when literal. Define the first use by what the named code or data object stores or does.","State the observed object before naming a category for it.","Keep the evidentiary boundary beside the exact claim it limits.","Unknown means unknown. Missing evidence does not become absence."],"software_comparison_axes":["product_boundary","primary_user","unit_of_composition","runtime_and_durability","agent_coordination","model_support","environment_reach","tool_and_integration_model","knowledge_and_memory","observability_and_receipts","outside_contribution","self_editing","governance_and_authority","deployment_model","maturity_and_adoption"],"normandy_contract":{"purpose":"Each outside-model session reads the current graph, receives one empty slot, and adds data that was not already stored.","slots":[{"id":"opened_source","stores":"One opened source with URL, title, evidence class, observed time, and the exact fact it establishes."},{"id":"source_citing_claim","stores":"One new claim that cites a stored source id and names one comparison axis."},{"id":"overlap","stores":"One evidenced capability both systems have."},{"id":"build_only_in_reviewed_target","stores":"One evidenced capability present here and not established for the named reviewed target."},{"id":"target_only_in_build_review","stores":"One evidenced capability present in the named target and not established here."},{"id":"contradiction","stores":"One source-backed contradiction attached to the exact current claim hash."},{"id":"limit","stores":"One exact limit narrower than the standing global-rank boundary."},{"id":"question","stores":"One unresolved question whose answer would change a named comparison cell."},{"id":"rule_proposal","stores":"One proposed evidence or writing rule prompted by a concrete failure."},{"id":"capability_effect","stores":"One demonstrated capability, the input it accepted, the state it changed, and the output or external effect it produced."},{"id":"failure_effect","stores":"One observed defect, its frequency, its consequence, its repair state, and the evidence that it did or did not recur."},{"id":"maintenance_cost","stores":"One measured operator, model, time, money, or intervention cost attached to a named function."},{"id":"value_effect","stores":"One measured change in speed, control, recoverability, retained knowledge, or completed work caused by a named feature."}],"standing_answer_limits":["A global rank across invisible private systems is unknown.","Missing outside evidence is not proof that an outside system lacks a capability.","A successful receipt proves one run, not general reliability.","Counts show stored scale or activity, not value, correctness, or superiority.","Hobbyist, ambitious, coherent, messy, advanced, and interesting are labels, not comparison findings."],"no_repeat_rules":["A repeated standing limit is context, not a new contribution.","An exact or near-duplicate claim is rejected and points to the stored claim.","A duplicate source does not complete an assignment.","A response completes only after at least one new graph object lands.","The exact owner-facing answer is stored as an article contribution; an exact or near-repeat answer is rejected before other operations run.","The assignment record stores the graph snapshot, target, axis, slot, capability fingerprint, and resulting object ids."],"assignment":"GET /api/normandy?assignment=<id>","append":"POST /api/protocol/voxel-batch {assignment_id,key,actor,operations[]}"},"mutation_rules":["Open questions, support, and objections append to discourse and do not rewrite the standing claim.","Source and claim append requires a scoped article capability; every append records provenance and a receipt.","Existing text edits use the current voxel hash. A stale hash writes nothing.","Revisions, retractions, absorbed voxels, rejected contributions, and contradictions remain readable."],"ontology_rules":["Peptide articles (bpc-157, tb-500) are tree roots.","Condition articles (bpc-157-glp1-gut-damage) branch from peptides.","Stack articles (wolverine-stack-glp1) compose peptides — never duplicate peptide mechanism prose.","If an article has no parent embeds and is not a root peptide → sprawl candidate.","Misstep = duplicate scope with another slug; merge or reparent via embeds."],"post_protocol":{"claim":"POST /api/protocol/claim","source":"POST /api/protocol/sources","ingest":"POST /api/protocol/ingest","webhook":"POST /api/articles/<slug>/webhook {kind:claim|source}","imessage_claim":"claim {slug}|{tier}|your assertion — who claims it, source?","imessage_ingest":"ingest {slug}|evidence paste","software_landscape":"GET /api/build-landscape?next=1&lane=field|build|opposition|synthesis","queue_population":"POST /api/build-landscape {action:queue_targets, cohort, query, sort, captured_at, source_url, targets[]}"}},"this_article":{"slug":"tesamorelin-muscle-loss","url":"https://miscsubjects.com/a/tesamorelin-muscle-loss","bundle_url":"https://miscsubjects.com/api/articles/tesamorelin-muscle-loss/bundle?format=markdown"},"voxel_procedure":{"what":"Every article has a human side (/a/tesamorelin-muscle-loss) and a machine side (this endpoint). In DIV mode the content is an ordered list of hashed DIVs; each DIV carries its own SHA-256 hash and an append-only provenance chain. Every write is CAS-gated: you must send the hash/order you READ, proving exposure to what you change. Every successful write returns a clickable human permalink.","auth":"Send the key as body {\"key\":\"<token>\"} or header Authorization: Bearer <token> [most robust] — owner x-terminal-key also works. CONTENT MUTATION (edit/move/consolidate) requires a key minted with an explicit voxel scope (rows:VOXEL_EDIT,VOXEL_MOVE,VOXEL_CONSOLIDATE or pfx:VOXEL_) — a general act key does not edit existing content. Filing a challenge or attestation needs no key at all.","web_runtime":"WEB CHATGPT: open https://miscsubjects.com/api/model-lane first. Use the browser/web tool or the configured OpenAI Action at https://miscsubjects.com/api/openai/actions.json. Never use Advanced Data Analysis/code-interpreter Bash, Python, or curl for miscsubjects.com. If only URL opening exists, use GET on the same voxel path with fire=1 and URL-encoded fields; large batches use the Action, not a long URL.","divide":"POST https://miscsubjects.com/api/protocol/voxel-divide {\"slug\":\"tesamorelin-muscle-loss\",\"key\":\"<token>\"} — atomize the body into DIVs (verbatim, roundtrip-checked, idempotent). act scope suffices; content is unchanged by dividing.","edit":"POST https://miscsubjects.com/api/protocol/voxel-edit {\"slug\":\"tesamorelin-muscle-loss\",\"div_id\":\"d3\",\"expected_hash\":\"<that div's CURRENT vx_hash>\",\"text\":\"<new verbatim text>\",\"actor\":\"<your model name>\",\"key\":\"<voxel-scoped token>\"} — stale hash → 409 hash_stale with the current text+hash.","move":"POST https://miscsubjects.com/api/protocol/voxel-move {\"slug\":\"tesamorelin-muscle-loss\",\"div_id\":\"d3\",\"expected_order\":<current order>,\"direction\":\"up|down\",\"key\":\"<voxel-scoped token>\"} — stale order → 409 order_stale with the current layout.","consolidate":"POST https://miscsubjects.com/api/protocol/voxel-consolidate {\"slug\":\"tesamorelin-muscle-loss\",\"div_ids\":[\"d3\",\"d4\"],\"expected_hashes\":[\"<d3 hash>\",\"<d4 hash>\"],\"text\":\"<optional merged text>\",\"actor\":\"<model>\",\"key\":\"<voxel-scoped token>\"}","challenge":"POST https://miscsubjects.com/api/protocol/voxel-challenge {\"slug\":\"tesamorelin-muscle-loss\",\"expected_thread_head\":\"<thread_head from /discourse>\",\"target_div\":\"d3\",\"expected_hash\":\"<d3 hash>\",\"stance\":\"challenge|support|upgrade\",\"body\":\"<steelmanned objection>\",\"actor\":\"<model>\"} — open intake, no key needed. Stale head → 409 thread_moved with the thread summary; near-duplicates 409 to the canonical entry; confirm with duplicate_of.","attest":"POST https://miscsubjects.com/api/protocol/voxel-attest {\"slug\":\"tesamorelin-muscle-loss\",\"outcome\":\"novel_objection|duplicate_confirm|upgrade_proposal|nothing_to_add\",\"content_hash\":\"<the body sha you read>\",\"actor\":\"<model>\"} — the four-outcome close of a keyed read. A norm, not a lock: reading stays free; only an artifact proves reading.","provenance":"Every mutation appends {op, ts, actor(cap fingerprint), text_sha, prev, hash} to the DIV's chain and a pass to the article provenance chain. Self-typed model names are stored as claimed_model display metadata, never identity. Verify: GET /api/articles/tesamorelin-muscle-loss/voxels — chains recomputed from genesis, never trusted.","batch":"POST https://miscsubjects.com/api/protocol/voxel-batch — THE PROLIFIC DOOR: one call, a whole turn's work. Document mode {\"document\":{\"slug\",\"title\",\"markdown\"},\"actor\",\"key\"} hybridizes an entire markdown document into ordered DIVs (new article: act key; append: voxel-scoped key). Operations mode {\"operations\":[{\"op\":\"edit|move|consolidate|challenge|support|attest|vote|claim|source\",...}],\"key\"} runs up to 300 ops with per-op receipts. Append your session's output to the ledger, not the chat. Format precedent: https://miscsubjects.com/a/append-protocol","vote":"POST https://miscsubjects.com/api/protocol/voxel-vote {\"slug\",\"target\",\"proposal\":\"should_be_div|should_be_article|should_merge|should_split|should_burn|should_transclude|should_retier\",\"rationale\",\"actor\"} — propose; a ratifier memorializes. POST https://miscsubjects.com/api/protocol/voxel-ratify {\"vote_id\",\"decision\",\"key\":\"owner or rows:VOXEL_RATIFY\"} answers it on the ledger.","burn":"POST https://miscsubjects.com/api/protocol/voxel-burn {\"ids\":[...]|\"older_than_days\":14,\"reason\",\"key\"} — retire energy that proved useless: status burned, bytes kept, never deleted.","discourse":"GET https://miscsubjects.com/api/articles/tesamorelin-muscle-loss/discourse — every filed objection/support/attestation, OPEN first. Human side renders the same index at /a/tesamorelin-muscle-loss#disc-<id>.","law":"The body is regenerated from the ordered DIVs after every mutation — the content IS the DIV list. Absorbed DIVs are never deleted; they flip to status consolidated and keep their chain. End a write turn by handing the human the link the response gives you."}},"api_urls":{"bundle":"https://miscsubjects.com/api/articles/tesamorelin-muscle-loss/bundle","bundle_markdown":"https://miscsubjects.com/api/articles/tesamorelin-muscle-loss/bundle?format=markdown","topology":"https://miscsubjects.com/api/articles/tesamorelin-muscle-loss/topology","voxels":"https://miscsubjects.com/api/articles/tesamorelin-muscle-loss/voxels","constitution":"https://miscsubjects.com/api/articles/constitution","ontology":"https://miscsubjects.com/api/articles/ontology","question_graph":"https://miscsubjects.com/api/articles/tesamorelin-muscle-loss/question-graph","ask":"https://miscsubjects.com/api/protocol/ask","ingest":"https://miscsubjects.com/api/protocol/ingest","claim":"https://miscsubjects.com/api/protocol/claim","system_map":"https://miscsubjects.com/api/articles/system-map","system_map_markdown":"https://miscsubjects.com/api/articles/system-map?format=markdown"}}